ReviewGlobal cardiology science & practice2014
Tissue plasminogen activator-based clot busting: Controlled delivery approaches.
Review in Global cardiology science & practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- The Phytochemical Investigation, Thrombolytic, and Antioxidant Activity of Clerodendrum thomsoniae Balf.Chemistry & biodiversity · 2026Article
- Nutritional Advantages of Walnut (Food science & nutrition · 2025Review
- Application of nanoultrasonography in early diagnosis of coronary heart disease.Nanomedicine (London, England) · 2025Review
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Article
- Fibrin-specific poly(N-isopropylacrylamide) nanogels for targeted delivery of tissue-type plasminogen activator to treat thrombotic complications are well tolerated in vivo.Bioengineering & translational medicine · 2022Article
- Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.Journal of thrombosis and thrombolysis · 2021Article
- The promising shadow of microbubble over medical sciences: from fighting wide scope of prevalence disease to cancer eradication.Journal of biomedical science · 2021Review
- Vascular Nanomedicine: Current Status, Opportunities, and Challenges.Seminars in thrombosis and hemostasis · 2020Review
- Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.Nanoscale horizons · 2020Review
- An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.International journal of nanomedicine · 2020Article
- Engineered microparticles and nanoparticles for fibrinolysis.Journal of thrombosis and haemostasis : JTH · 2019Review
- Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.Expert opinion on drug delivery · 2018Article
- Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases are the leading cause of death worldwide. Thrombosis, the formation of blood clot (thrombus) in the circulatory system obstructing the blood flow, is one of the main causes behind various ischemic arterial syndromes such as ischemic stroke and myocardial infarction, as well as vein syndromes such as deep vein thrombosis, and consequently, pulmonary emboli. Several thrombolytic agents have been developed for treating thrombosis, the most common being tissue plasminogen activator (tPA), administrated systemically or locally via IV infusion directly proximal to the thrombus, with the aim of restoring and improving the blood flow. TPA triggers the dissolution of thrombi by inducing the conversion of plasminogen to protease plasmin followed by fibrin digestion that eventually leads to clot lysis. Although tPA provides powerful thrombolytic activity, it has many shortcomings, including poor pharmacokinetic profiles, impairment of the reestablishment of normal coronary flow, and impairment of hemostasis, leading to life-threatening bleeding consequences. The bleeding consequence is ascribed to the ability of tPA to circulate throughout the body and therefore can lysis all blood clots in the circulation system, even the good ones that prevent the bleeding and promote injury repair. This review provides an overview of the different delivery approaches for tPA including: liposomes, ultrasound-triggered thrombolysis, anti-fibrin antibody-targeted tPA, camouflaged-tPA, tpA-loaded microcarriers, and nano-modulated delivery approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.